SunTrust Banks Brokers Raise Earnings Estimates for Bausch Health Companies Inc (NYSE:BHC)

Bausch Health Companies Inc (NYSE:BHC) – Research analysts at SunTrust Banks lifted their Q3 2019 earnings estimates for Bausch Health Companies in a research report issued on Monday, August 12th. SunTrust Banks analyst G. Gilbert now forecasts that the company will post earnings of $1.03 per share for the quarter, up from their prior forecast of $0.95. SunTrust Banks also issued estimates for Bausch Health Companies’ FY2020 earnings at $4.20 EPS, FY2021 earnings at $4.86 EPS, FY2022 earnings at $5.45 EPS and FY2023 earnings at $5.84 EPS.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The company had revenue of $2.15 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same period last year, the firm posted $0.93 EPS. The company’s revenue was up 1.1% compared to the same quarter last year.

BHC has been the topic of a number of other research reports. TD Securities raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Thursday. ValuEngine raised shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Monday, July 29th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a research report on Monday, July 15th. Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Finally, Cantor Fitzgerald set a $32.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Friday, May 31st. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company’s stock. Bausch Health Companies presently has an average rating of “Buy” and an average price target of $29.68.

Shares of BHC stock opened at $20.88 on Thursday. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45. The firm’s fifty day simple moving average is $23.79 and its 200 day simple moving average is $23.91. The firm has a market capitalization of $7.85 billion, a P/E ratio of 5.19, a price-to-earnings-growth ratio of 0.26 and a beta of 0.76. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 8.94.

A number of institutional investors and hedge funds have recently bought and sold shares of BHC. Highstreet Asset Management Inc. acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $354,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bausch Health Companies by 1.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 193,792 shares of the company’s stock valued at $4,783,000 after purchasing an additional 2,223 shares in the last quarter. CLARET ASSET MANAGEMENT Corp boosted its stake in shares of Bausch Health Companies by 9.2% in the 1st quarter. CLARET ASSET MANAGEMENT Corp now owns 14,751 shares of the company’s stock valued at $364,000 after purchasing an additional 1,245 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock valued at $91,441,000 after purchasing an additional 815,311 shares in the last quarter. Finally, Academy Capital Management Inc. TX boosted its stake in shares of Bausch Health Companies by 3.9% in the 1st quarter. Academy Capital Management Inc. TX now owns 580,218 shares of the company’s stock valued at $14,331,000 after purchasing an additional 21,641 shares in the last quarter. Hedge funds and other institutional investors own 53.70% of the company’s stock.

In other Bausch Health Companies news, EVP Christina Ackermann sold 3,418 shares of Bausch Health Companies stock in a transaction on Monday, August 12th. The shares were sold at an average price of $22.45, for a total transaction of $76,734.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 11.87% of the stock is owned by insiders.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: What Factors Can Affect Return on Equity?

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.